BioCentury
ARTICLE | Clinical News

Alogliptin regulatory update

March 9, 2009 7:00 AM UTC

Takeda said FDA does not find existing data on alogliptin (SYR-322) sufficient to meet requirements set out in a December 2008 guidance on cardiovascular risk evaluation for diabetes treatments. The P...